Precision Dosing of Cannabinoids: Knowns & Unknowns
4:00 PM - 5:00 PM
Recent developments with regard to medicinal and recreational marijuana legislation in the United States has led to a significant increase in self medication with cannabis. However, due to the position of the federal government, severe restrictions on research remain in place. Thus, important details remain undiscovered, which presents substantial barriers for clinicians, pharmacists and patients. As a result, there is an excess of anecdotal and misinformation regarding appropriate dosing, indications to be treated, most effective route of administration, etc.
This presentation will cover many aspects of medicinal cannabinoids based on what is currently known from the most recent scientific research literature. In addition to the challenges associated with cannabinoid therapy, the associated bioavailability of different routes of administration ranging from inhalation to transdermal, and appropriate dosing will be discussed. The unique role of the Endocannabinoid system in human pathophysiology as well as the general pharmacology of cannabinoids will also be covered. Specific indications that show promise for cannabinoid based therapies and current cannabinoid based pharmaceuticals and their approved indications will also be described. Finally, what is known and what is unknown regarding cannabinoid therapies will be summarized and the future of cannabinoids as medicine will be discussed.
Jeremy Riggle, Ph.D., Chief Scientist